Combination of salinomycin and radiation effectively eliminates head and neck squamous cell carcinoma cells in vitro

Gehrke,Thomas; Hackenberg,Stephan; Polat,Bülent; Wohlleben,Gisela; Hagen,Rudolf; Kleinsasser,Norbert; Scherzad,Agmal

doi:10.3892/or.2018.6267

Combination of salinomycin and radiation effectively eliminates head and neck squamous cell carcinoma cells in vitro

Authors:
- Thomas Gehrke
- Stephan Hackenberg
- Bülent Polat
- Gisela Wohlleben
- Rudolf Hagen
- Norbert Kleinsasser
- Agmal Scherzad
View Affiliations

Affiliations: Department of Otorhinolaryngology, Head and Neck Surgery, University Hospital, D-97080 Wuerzburg, Germany, Department of Radiooncology, Head and Neck Surgery, University Hospital, D-97080 Wuerzburg, Germany
Published online on: February 13, 2018 https://doi.org/10.3892/or.2018.6267
Pages: 1991-1998

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The antibiotic drug salinomycin has been reported to mediate cancer cell-specific cytotoxicity, especially regarding cancer stem cells. Since salinomycin has also been reported to arrest cancer cells in the G2 phase, it may have possible radiosensitizing effects. Radiotherapy is a common therapeutic strategy for head and neck squamous cell carcinoma (HNSCC). The aim of the present study was to evaluate a possible influence of salinomycin on the radiosensitivity of the HNSCC cell line HLaC-78 in vitro. HLaC-78 cells were incubated with 5 µM salinomycin or control medium for 24 h and then received 5-Gy irradiation. Subsequently, analysis of cell viability, apoptosis, necrosis and motility through an MTT and a colony formation assay, as well as an Annexin V/propidium-iodide test, a consecutive cell count for four days and a scratch assay were conducted. Additionally, interleukin-8 secretion was assessed using ELISA, due to its role in tumor progression and angiogenesis. Combined treatment with salinomycin and radiation revealed a significantly higher reduction of tumor cell viability, proliferation, motility and secretory capacity compared to cells receiving only one of the treatments alone. Therefore, it is postulated that radiation and salinomycin are an effective combination therapy against HNSCC, a hypothesis which warrants further investigation in cell lines, as well as in an animal model.

View Figures

View References

1	Siegel RL, Miller KD and Jemal A: Cancer statistics, 2016. CA Cancer J Clin. 66:7–30. 2016. View Article : Google Scholar : PubMed/NCBI
2	Seiwert TY and Cohen EE: State-of-the-art management of locally advanced head and neck cancer. Br J Cancer. 92:1341–1348. 2005. View Article : Google Scholar : PubMed/NCBI
3	Miller KD, Siegel RL, Lin CC, Mariotto AB, Kramer JL, Rowland JH, Stein KD, Alteri R and Jemal A: Cancer treatment and survivorship statistics, 2016. CA Cancer J Clin. 66:271–289. 2016. View Article : Google Scholar : PubMed/NCBI
4	Vermorken JB, Remenar E, van Herpen C, Gorlia T, Mesia R, Degardin M, Stewart JS, Jelic S, Betka J, Preiss JH, et al: Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer. N Engl J Med. 357:1695–1704. 2007. View Article : Google Scholar : PubMed/NCBI
5	Douple EB and Richmond RC: A review of platinum complex biochemistry suggests a rationale for combined platinum-radiotherapy. Int J Radiat Oncol Biol Phys. 5:1335–1339. 1979. View Article : Google Scholar : PubMed/NCBI
6	Rockwell S and Kennedy KA: Combination therapy with radiation and mitomycin C: Preliminary results with EMT6 tumor cells in vitro and in vivo. Int J Radiat Oncol Biol Phys. 5:1673–1676. 1979. View Article : Google Scholar : PubMed/NCBI
7	Wennerberg J, Alm P, Biörklund A, Killander D, Långström E and Tropé C: Cell cycle perturbations in heterotransplanted squamous-cell carcinoma of the head and neck after mitomycin C and cisplatin treatment. Int J Cancer. 33:213–222. 1984. View Article : Google Scholar : PubMed/NCBI
8	Gomez-Millan J, Fernández JR and Medina Carmona JA: Current status of IMRT in head and neck cancer. Rep Pract Oncol Radiother. 18:371–375. 2013. View Article : Google Scholar : PubMed/NCBI
9	Prestwich RJ, Öksüz DÇ, Dyker K, Coyle C and Şen M: Feasibility and efficacy of induction docetaxel, cisplatin, and 5-fluorouracil chemotherapy combined with cisplatin concurrent chemoradiotherapy for nonmetastatic Stage IV head-and-neck squamous cell carcinomas. Int J Radiat Oncol Biol Phys. 81:e237–243. 2011. View Article : Google Scholar : PubMed/NCBI
10	Miyazaki Y, Shibuya M, Sugawara H, Kawaguchi O and Hirsoe C: Salinomycin, a new polyether antibiotic. J Antibiot. 27:814–821. 1974. View Article : Google Scholar : PubMed/NCBI
11	Danforth HD, Ruff MD, Reid WM and Miller RL: Anticoccidial activity of salinomycin in battery raised broiler chickens. Poult Sci. 56:926–932. 1977. View Article : Google Scholar : PubMed/NCBI
12	Naujokat C, Fuchs D and Opelz G: Salinomycin in cancer: A new mission for an old agent. Mol Med Rep. 3:555–559. 2010. View Article : Google Scholar : PubMed/NCBI
13	Gupta PB, Onder TT, Jiang G, Tao K, Kuperwasser C, Weinberg RA and Lander ES: Identification of selective inhibitors of cancer stem cells by high-throughput screening. Cell. 138:645–659. 2009. View Article : Google Scholar : PubMed/NCBI
14	Pries R, Wittkopf N, Hasselbacher K and Wollenberg B: Constitutive expression of the potential stem cell marker CD44 in permanent HNSCC cell lines. HNO. 56:461–466. 2008.(In German). View Article : Google Scholar : PubMed/NCBI
15	Boman BM and Wicha MS: Cancer stem cells: A step toward the cure. J Clin Oncol. 26:2795–2799. 2008. View Article : Google Scholar : PubMed/NCBI
16	Davis SJ, Divi V, Owen JH, Bradford CR, Carey TE, Papagerakis S and Prince ME: Metastatic potential of cancer stem cells in head and neck squamous cell carcinoma. Arch Otolaryngol Head Neck Surg. 136:1260–1266. 2010. View Article : Google Scholar : PubMed/NCBI
17	Arafat K, Iratni R, Takahashi T, Parekh K, Al Dhaheri Y, Adrian TE and Attoub S: Inhibitory effects of salinomycin on cell survival, colony growth, migration, and invasion of human non-small cell lung cancer A549 and LNM35: Involvement of NAG-1. PLoS One. 8:e669312013. View Article : Google Scholar : PubMed/NCBI
18	Al Dhaheri Y, Attoub S, Arafat K, Abuqamar S, Eid A, Al Faresi N and Iratni R: Salinomycin induces apoptosis and senescence in breast cancer: Upregulation of p21, downregulation of survivin and histone H3 and H4 hyperacetylation. Biochim Biophys Acta. 1830:3121–3135. 2013. View Article : Google Scholar : PubMed/NCBI
19	Zhi QM, Chen XH, Ji J, Zhang JN, Li JF, Cai Q, Liu BY, Gu QL, Zhu ZG and Yu YY: Salinomycin can effectively kill ALDH^high stem-like cells on gastric cancer. Biomed Pharmacother. 65:509–515. 2011. View Article : Google Scholar : PubMed/NCBI
20	Lu D, Choi MY, Yu J, Castro JE, Kipps TJ and Carson DA: Salinomycin inhibits Wnt signaling and selectively induces apoptosis in chronic lymphocytic leukemia cells. Proc Natl Acad Sci USA. 108:pp. 13253–13257. 2011; View Article : Google Scholar : PubMed/NCBI
21	Scherzed A, Hackenberg S, Froelich K, Rak K, Ginzkey C, Hagen R, Schendzielorz P and Kleinsasser N: Effects of salinomycin and CGP37157 on head and neck squamous cell carcinoma cell lines in vitro. Mol Med Rep. 12:4455–4461. 2015. View Article : Google Scholar : PubMed/NCBI
22	Wang F, He L, Dai WQ, Xu YP, Wu D, Lin CL, Wu SM, Cheng P, Zhang Y, Shen M, et al: Salinomycin inhibits proliferation and induces apoptosis of human hepatocellular carcinoma cells in vitro and in vivo. PLoS One. 7:e506382012. View Article : Google Scholar : PubMed/NCBI
23	Wu D, Zhang Y, Huang J, Fan Z, Shi F and Wang S: Salinomycin inhibits proliferation and induces apoptosis of human nasopharyngeal carcinoma cell in vitro and suppresses tumor growth in vivo. Biochem Biophys Res Commun. 443:712–717. 2014. View Article : Google Scholar : PubMed/NCBI
24	Kim KY, Yu SN, Lee SY, Chun SS, Choi YL, Park YM, Song CS, Chatterjee B and Ahn SC: Salinomycin-induced apoptosis of human prostate cancer cells due to accumulated reactive oxygen species and mitochondrial membrane depolarization. Biochem Biophys Res Commun. 413:80–86. 2011. View Article : Google Scholar : PubMed/NCBI
25	Parajuli B, Lee HG, Kwon SH, Cha SD, Shin SJ, Lee GH, Bae I and Cho CH: Salinomycin inhibits Akt/NF-kappaB and induces apoptosis in cisplatin resistant ovarian cancer cells. Cancer Epidemiol. 37:512–517. 2013. View Article : Google Scholar : PubMed/NCBI
26	Parajuli B, Shin SJ, Kwon SH, Cha SD, Chung R, Park WJ, Lee HG and Cho CH: Salinomycin induces apoptosis via death receptor-5 up-regulation in cisplatin-resistant ovarian cancer cells. Anticancer Res. 33:1457–1462. 2013.PubMed/NCBI
27	Ko JC, Zheng HY, Chen WC, Peng YS, Wu CH, Wei CL, Chen JC and Lin YW: Salinomycin enhances cisplatin-induced cytotoxicity in human lung cancer cells via down-regulation of AKT-dependent thymidylate synthase expression. Biochem Pharmacol. 122:90–98. 2016. View Article : Google Scholar : PubMed/NCBI
28	Muntimadugu E, Kumar R, Saladi S, Rafeeqi TA and Khan W: CD44 targeted chemotherapy for co-eradication of breast cancer stem cells and cancer cells using polymeric nanoparticles of salinomycin and paclitaxel. Colloids Surf B Biointerfaces. 143:532–546. 2016. View Article : Google Scholar : PubMed/NCBI
29	Zhang GN, Liang Y, Zhou LJ, Chen SP, Chen G, Zhang TP, Kang T and Zhao YP: Combination of salinomycin and gemcitabine eliminates pancreatic cancer cells. Cancer Lett. 313:137–144. 2011. View Article : Google Scholar : PubMed/NCBI
30	Kim JH, Chae M, Kim WK, Kim YJ, Kang HS, Kim HS and Yoon S: Salinomycin sensitizes cancer cells to the effects of doxorubicin and etoposide treatment by increasing DNA damage and reducing p21 protein. Br J Pharmacol. 162:773–784. 2011. View Article : Google Scholar : PubMed/NCBI
31	Zhang B, Wang X, Cai F, Chen W, Loesch U and Zhong XY: Antitumor properties of salinomycin on cisplatin-resistant human ovarian cancer cells in vitro and in vivo: Involvement of p38 MAPK activation. Oncol Rep. 29:1371–1378. 2013. View Article : Google Scholar : PubMed/NCBI
32	Zhou J, Li P, Xue X, He S, Kuang Y, Zhao H, Chen S, Zhi Q and Guo X: Salinomycin induces apoptosis in cisplatin-resistant colorectal cancer cells by accumulation of reactive oxygen species. Toxicol Lett. 222:139–145. 2013. View Article : Google Scholar : PubMed/NCBI
33	Kim WK, Kim JH, Yoon K, Kim S, Ro J, Kang HS and Yoon S: Salinomycin, a p-glycoprotein inhibitor, sensitizes radiation-treated cancer cells by increasing DNA damage and inducing G2 arrest. Invest New Drugs. 30:1311–1318. 2012. View Article : Google Scholar : PubMed/NCBI
34	Zhao SJ, Wang XJ, Wu QJ, Liu C, Li DW, Fu XT, Zhang HF, Shao LR, Sun JY, Sun BL, et al: Induction of G1 cell cycle arrest in human glioma cells by salinomycin through triggering ROS-mediated DNA damage in vitro and in vivo. Neurochem Res. 42:997–1005. 2017. View Article : Google Scholar : PubMed/NCBI
35	Masuya D, Huang C, Liu D, Kameyama K, Hayashi E, Yamauchi A, Kobayashi S, Haba R and Yokomise H: The intratumoral expression of vascular endothelial growth factor and interleukin-8 associated with angiogenesis in nonsmall cell lung carcinoma patients. Cancer. 92:2628–2638. 2001. View Article : Google Scholar : PubMed/NCBI
36	Yuan A, Yang PC, Yu CJ, Chen WJ, Lin FY, Kuo SH and Luh KT: Interleukin-8 messenger ribonucleic acid expression correlates with tumor progression, tumor angiogenesis, patient survival, and timing of relapse in non-small-cell lung cancer. Am J Respir Crit Care Med. 162:1957–1963. 2000. View Article : Google Scholar : PubMed/NCBI
37	Gehrke T, Scherzad A, Hackenberg S, Ickrath P, Schendzielorz P, Hagen R and Kleinsasser N: Additive antitumor effects of celecoxib and simvastatin on head and neck squamous cell carcinoma in vitro. Int J Oncol. 51:931–938. 2017. View Article : Google Scholar : PubMed/NCBI
38	Mosmann T: Rapid colorimetric assay for cellular growth and survival: Application to proliferation and cytotoxicity assays. J Immunol Methods. 65:55–63. 1983. View Article : Google Scholar : PubMed/NCBI
39	Perri F, Pacelli R, Della Vittoria Scarpati G, Cella L, Giuliano M, Caponigro F and Pepe S: Radioresistance in head and neck squamous cell carcinoma: Biological bases and therapeutic implications. Head Neck. 37:763–770. 2015. View Article : Google Scholar : PubMed/NCBI
40	Bussmann L, Busch CJ, Lörincz BB, Rieckmann T, Block A and Knecht R: Perspectives in chemosensitivity and chemoresistance assays and their implementation in head and neck cancer. Eur Arch Otorhinolaryngol. 273:4073–4080. 2016. View Article : Google Scholar : PubMed/NCBI
41	Riley JL: Combination checkpoint blockade-taking melanoma immunotherapy to the next level. N Engl J Med. 369:187–189. 2013. View Article : Google Scholar : PubMed/NCBI
42	Michot JM, Lazarovici J, Ghez D, Danu A, Fermé C, Bigorgne A, Ribrag V, Marabelle A and Aspeslagh S: Challenges and perspectives in the immunotherapy of Hodgkin lymphoma. Eur J Cancer. 85:67–77. 2017. View Article : Google Scholar : PubMed/NCBI
43	Mann JE, Hoesli R, Michmerhuizen NL, Devenport SN, Ludwig ML, Vandenberg TR, Matovina C, Jawad N, Mierzwa M, Shuman AG, et al: Surveilling the potential for precision medicine-driven PD-1/PD-L1-targeted therapy in HNSCC. J Cancer. 8:332–344. 2017. View Article : Google Scholar : PubMed/NCBI
44	Wood O, Clarke J, Woo J, Mirza AH, Woelk CH, Thomas GJ, Vijayanand P, King E and Ottensmeier CH: Head and neck squamous cell carcinomas are characterized by a stable immune signature within the primary tumor over time and space. Clin Cancer Res. 23:7641–7649. 2017. View Article : Google Scholar : PubMed/NCBI
45	Reya T, Morrison SJ, Clarke MF and Weissman IL: Stem cells, cancer, and cancer stem cells. Nature. 414:105–111. 2001. View Article : Google Scholar : PubMed/NCBI
46	Pardal R, Clarke MF and Morrison SJ: Applying the principles of stem-cell biology to cancer. Nat Rev Cancer. 3:895–902. 2003. View Article : Google Scholar : PubMed/NCBI
47	Hermann PC, Bhaskar S, Cioffi M and Heeschen C: Cancer stem cells in solid tumors. Semin Cancer Biol. 20:77–84. 2010. View Article : Google Scholar : PubMed/NCBI
48	Tehranchi R, Woll PS, Anderson K, Buza-Vidas N, Mizukami T, Mead AJ, Astrand-Grundström I, Strömbeck B, Horvat A, Ferry H, et al: Persistent malignant stem cells in del(5q) myelodysplasia in remission. N Engl J Med. 363:1025–1037. 2010. View Article : Google Scholar : PubMed/NCBI
49	Creighton CJ, Li X, Landis M, Dixon JM, Neumeister VM, Sjolund A, Rimm DL, Wong H, Rodriguez A, Herschkowitz JI, et al: Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features. Proc Natl Acad Sci USA. 106:pp. 13820–13825. 2009; View Article : Google Scholar : PubMed/NCBI
50	Teng Y, Wang X, Wang Y and Ma D: Wnt/beta-catenin signaling regulates cancer stem cells in lung cancer A549 cells. Biochem Biophys Res Commun. 392:373–379. 2010. View Article : Google Scholar : PubMed/NCBI
51	Viale A, De Franco F, Orleth A, Cambiaghi V, Giuliani V, Bossi D, Ronchini C, Ronzoni S, Muradore I, Monestiroli S, et al: Cell-cycle restriction limits DNA damage and maintains self-renewal of leukaemia stem cells. Nature. 457:51–56. 2009. View Article : Google Scholar : PubMed/NCBI
52	Dean M: ABC transporters, drug resistance, and cancer stem cells. J Mammary Gland Biol Neoplasia. 14:3–9. 2009. View Article : Google Scholar : PubMed/NCBI
53	Kobune M, Takimoto R, Murase K, Iyama S, Sato T, Kikuchi S, Kawano Y, Miyanishi K, Sato Y, Niitsu Y and Kato J: Drug resistance is dramatically restored by hedgehog inhibitors in CD34⁺ leukemic cells. Cancer Sci. 100:948–955. 2009. View Article : Google Scholar : PubMed/NCBI
54	Zhou Y, Zhou Y, Shingu T, Feng L, Chen Z, Ogasawara M, Keating MJ, Kondo S and Huang P: Metabolic alterations in highly tumorigenic glioblastoma cells: Preference for hypoxia and high dependency on glycolysis. J Biol Chem. 286:32843–32853. 2011. View Article : Google Scholar : PubMed/NCBI
55	Baumann M, Krause M and Hill R: Exploring the role of cancer stem cells in radioresistance. Nat Rev Cancer. 8:545–554. 2008. View Article : Google Scholar : PubMed/NCBI
56	Lagadec C, Vlashi E, Della Donna L, Meng Y, Dekmezian C, Kim K and Pajonk F: Survival and self-renewing capacity of breast cancer initiating cells during fractionated radiation treatment. Breast Cancer Res. 12:R132010. View Article : Google Scholar : PubMed/NCBI
57	Wang Y: Effects of salinomycin on cancer stem cell in human lung adenocarcinoma A549 cells. Med Chem. 7:106–111. 2011. View Article : Google Scholar : PubMed/NCBI
58	Basu D, Montone KT, Wang LP, Gimotty PA, Hammond R, Diehl JA, Rustgi AK, Lee JT, Rasanen K, Weinstein GS and Herlyn M: Detecting and targeting mesenchymal-like subpopulations within squamous cell carcinomas. Cell Cycle. 10:2008–2016. 2011. View Article : Google Scholar : PubMed/NCBI
59	Fuchs D, Heinold A, Opelz G, Daniel V and Naujokat C: Salinomycin induces apoptosis and overcomes apoptosis resistance in human cancer cells. Biochem Biophys Res Commun. 390:743–749. 2009. View Article : Google Scholar : PubMed/NCBI
60	Fuchs D, Daniel V, Sadeghi M, Opelz G and Naujokat C: Salinomycin overcomes ABC transporter-mediated multidrug and apoptosis resistance in human leukemia stem cell-like KG-1a cells. Biochem Biophys Res Commun. 394:1098–1104. 2010. View Article : Google Scholar : PubMed/NCBI
61	Zhang G, Wang W, Yao C, Ren J, Zhang S and Han M: Salinomycin overcomes radioresistance in nasopharyngeal carcinoma cells by inhibiting Nrf2 level and promoting ROS generation. Biomed Pharmacother. 91:147–154. 2017. View Article : Google Scholar : PubMed/NCBI
62	Zhang Y, Zuo Y, Guan Z, Lu W, Xu Z, Zhang H, Yang Y, Yang M, Zhu H and Chen X: Salinomycin radiosensitizes human nasopharyngeal carcinoma cell line CNE-2 to radiation. Tumour Biol. 37:305–311. 2016. View Article : Google Scholar : PubMed/NCBI
63	Ketola K, Hilvo M, Hyötyläinen T, Vuoristo A, Ruskeepää AL, Orešič M, Kallioniemi O and Iljin K: Salinomycin inhibits prostate cancer growth and migration via induction of oxidative stress. Br J Cancer. 106:99–106. 2012. View Article : Google Scholar : PubMed/NCBI
64	Kim JH, Yoo HI, Kang HS, Ro J and Yoon S: Salinomycin sensitizes antimitotic drugs-treated cancer cells by increasing apoptosis via the prevention of G2 arrest. Biochem Biophys Res Commun. 418:98–103. 2012. View Article : Google Scholar : PubMed/NCBI
65	Bortner CD, Hughes FM Jr and Cidlowski JA: A primary role for K⁺ and Na⁺ efflux in the activation of apoptosis. J Biol Chem. 272:32436–32442. 1997. View Article : Google Scholar : PubMed/NCBI
66	Scherzad A, Hackenberg S, Froelich K, Rak K, Hagen R, Taeger J, Bregenzer M and Kleinsasser N: Chronic exposure of low dose salinomycin inhibits MSC migration capability in vitro. Biomed Rep. 4:325–330. 2016. View Article : Google Scholar : PubMed/NCBI
67	Sun J, Luo Q, Liu L, Yang X, Zhu S and Song G: Salinomycin attenuates liver cancer stem cell motility by enhancing cell stiffness and increasing F-actin formation via the FAK-ERK1/2 signalling pathway. Toxicology. 384:1–10. 2017. View Article : Google Scholar : PubMed/NCBI
68	Kopp F, Hermawan A, Oak PS, Herrmann A, Wagner E and Roidl A: Salinomycin treatment reduces metastatic tumor burden by hampering cancer cell migration. Mol Cancer. 13:162014. View Article : Google Scholar : PubMed/NCBI
69	Scherzad A, Hackenberg S, Schramm C, Froelich K, Ginzkey C, Hagen R and Kleinsasser N: Geno- and cytotoxicity of salinomycin in human nasal mucosa and peripheral blood lymphocytes. Toxicol In Vitro. 29:813–818. 2015. View Article : Google Scholar : PubMed/NCBI